| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Other Events
On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a re... |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease |
| 30 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
COMMERCIAL LEASE 1 Page PARTIES Bradford Street, LLC, LESSOR, which expression shall include heirs, successors, and assigns where the context so admits, does hereby lease to Aldeyra Therapeutics, Inc., 131 Hartwell Ave, Suite 320, Lexing... |
| 15 Jul 2026 |
8-K: Other Events
On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Applica... |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
Lexington, Mass., June 9, 2026 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appo... |
| 01 May 2026 |
8-K: Regulation FD Disclosure
Innovative Therapeutics for Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 |
| 20 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 01 Apr 2026 |
8-K: Other Events
As previously disclosed, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into that certain Loan and Security Agreement, dated as of March 25, 2019, by and among the Company, Helio Vision, LLC, the several banks and other ... |
| 17 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease |
| 31 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 16 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease |
| 13 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
2025 Research & Development Webcast CORPORATE OVERVIEW November 13, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025 Exhibit 99.1 |
| 28 Oct 2025 |
8-K: Other Events
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules |
| 19 Aug 2025 |
8-K: Financial Statements and Exhibits
LEXINGTON, Mass., August 19, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection... |
| 17 Jul 2025 |
8-K: Other Events
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease |
| 26 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma |
| 17 Jun 2025 |
8-K: Other Events
Lexington, Mass., June 17, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today ann... |
| 11 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2025 annual meeting of stockholders (the “Annual Meeting”) of Aldeyra Therapeutics, Inc. (the “Company”) held on June 10, 2025, the following proposals were submitted to the stockholders of the Company: |
| 06 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Topline Data Release and NDA Resubmission Plan REPROXALAP FOR THE POTENTIAL TREATMENT OF DRY EYE DISEASE May 6, 2025 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2025 Exhibit 99.1 |
| 17 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Lexington, Mass., April 17, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today an... |
Loading...